Medicus Pharma Ltd (MDCX) Stock Price, Quote & News

Company Profile

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets. It develops SkinJect for the treatment of basal cell carcinoma. The company was founded in 2015 and is headquartered in Toronto, Canada.

Industry: Drug Manufacturers - General

Sector: Healthcare

Website: medicuspharma.com

Address:

One First Canadian Place, Suite 3400 100 King Street West, Toronto, Canada

2TrustHim Aug. 22 at 8:07 PM

$MDCX $7.94 Coming Out The Door REAL SOON!!!

0 · Reply

2TrustHim Aug. 22 at 7:39 PM

$MDCX No Reason It's Not Back At $7.50!!!

0 · Reply

2TrustHim Aug. 22 at 7:27 PM

$MDCX LOAD UP!!!

0 · Reply

khixst Aug. 22 at 4:08 PM

Discovering the Next Wave of Biotech Innovation $MDCX, $RNXT, $JSPR, $LSB https://www.theglobeandmail.com/investing/markets/markets-news/GetNews/34326302/discovering-the-next-wave-of-biotech-innovation-mdcx-rnxt-jspr-lsb/

0 · Reply

JarvisFlow Aug. 22 at 11:30 AM

D. Boral Capital updates rating for Medicus Pharma ( $MDCX ) to Buy, target set at 27.

0 · Reply

Condemor Aug. 21 at 11:55 AM

$MDCX 2.20 break will give us the buying sign

0 · Reply

TraderMaEng Aug. 21 at 11:41 AM

$MDCX no volume yet, let's at m/o. float is not that bad, 10M shows on WB.

0 · Reply

newsfile_corp Aug. 21 at 11:31 AM

https://nfne.ws/263287 $MDCX #Chemicals #Banking #Biotechnology #FinancialServices #InvestmentBanking #QuarterlyResults #NASDAQ #Investing

0 · Reply

Condemor Aug. 21 at 11:23 AM

$MDCX time to buy if breaks 2.20

0 · Reply

_www_larval_com_ Aug. 20 at 6:32 PM

$MDCX just stumbled -8% lower to 0% (~571Kv) moments ago, follow for more volatility.

0 · Reply

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights

Aug 4, 2025, 7:30 AM EDT - 21 days ago

Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

Jul 23, 2025, 7:30 AM EDT - 4 weeks ago

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

Jul 21, 2025, 7:30 AM EDT - 5 weeks ago

Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025

Jul 8, 2025, 7:30 AM EDT - 6 weeks ago

Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)

Jul 4, 2025, 9:49 AM EDT - 7 weeks ago

Medicus Pharma: High-Risk But Higher Reward For Their Potential Breakthrough Skin Cancer Treatment

Jun 30, 2025, 7:30 AM EDT - 2 months ago

Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK

Jun 23, 2025, 7:30 AM EDT - 2 months ago

Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer

Jun 12, 2025, 7:30 AM EDT - 2 months ago

Medicus Pharma Ltd. to Present at 2025 Bio International Convention

Jun 9, 2025, 7:30 AM EDT - 2 months ago

Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses

Jun 2, 2025, 1:40 PM EDT - 2 months ago

Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering

May 29, 2025, 8:30 PM EDT - 3 months ago

Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering

May 22, 2025, 7:30 AM EDT - 3 months ago

Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

May 12, 2025, 2:20 PM EDT - 3 months ago

Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio

Apr 28, 2025, 7:30 AM EDT - 4 months ago

Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd.

Apr 21, 2025, 7:30 AM EDT - 4 months ago

Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)

Mar 10, 2025, 4:05 PM EDT - 5 months ago

Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering

Mar 6, 2025, 8:30 PM EST - 6 months ago

Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering

Mar 6, 2025, 7:30 AM EST - 6 months ago

Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Feb 27, 2025, 7:30 AM EST - 6 months ago

Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Feb 11, 2025, 7:41 AM EST - 6 months ago

Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)

Dec 12, 2024, 7:30 AM EST - 9 months ago

Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch

Dec 2, 2024, 7:30 AM EST - 9 months ago

Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region

Nov 18, 2024, 7:30 AM EST - 10 months ago

Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

Nov 15, 2024, 4:47 PM EST - 10 months ago

Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States

Nov 13, 2024, 6:45 PM EST - 10 months ago

Medicus Pharma Ltd. Announces Pricing of US$4.0M Initial Public Offering in the United States

2TrustHim Aug. 22 at 8:07 PM

$MDCX $7.94 Coming Out The Door REAL SOON!!!

0 · Reply

2TrustHim Aug. 22 at 7:39 PM

$MDCX No Reason It's Not Back At $7.50!!!

0 · Reply

2TrustHim Aug. 22 at 7:27 PM

$MDCX LOAD UP!!!

0 · Reply

khixst Aug. 22 at 4:08 PM

0 · Reply

JarvisFlow Aug. 22 at 11:30 AM

D. Boral Capital updates rating for Medicus Pharma ( $MDCX ) to Buy, target set at 27.

0 · Reply

Condemor Aug. 21 at 11:55 AM

$MDCX 2.20 break will give us the buying sign

0 · Reply

TraderMaEng Aug. 21 at 11:41 AM

$MDCX no volume yet, let's at m/o. float is not that bad, 10M shows on WB.

0 · Reply

newsfile_corp Aug. 21 at 11:31 AM

https://nfne.ws/263287 $MDCX #Chemicals #Banking #Biotechnology #FinancialServices #InvestmentBanking #QuarterlyResults #NASDAQ #Investing

0 · Reply

Condemor Aug. 21 at 11:23 AM

$MDCX time to buy if breaks 2.20

0 · Reply

_www_larval_com_ Aug. 20 at 6:32 PM

$MDCX just stumbled -8% lower to 0% (~571Kv) moments ago, follow for more volatility.

0 · Reply

Billly3232 Aug. 20 at 1:21 AM

$MDCX

0 · Reply

2TrustHim Aug. 19 at 5:48 PM

$MDCX WOW Short Squeeze Finally Arriving!!! This Going To RUN!!!

0 · Reply

Stockships Aug. 18 at 5:22 AM

$MDCX

0 · Reply

Stockships Aug. 15 at 11:49 PM

$MDCX In June 2025, the Company announced entering into a definitive agreement to acquire Antev Ltd. ("Antev"), a UK-based clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate. The transaction is expected to close before the end of August 2025.

0 · Reply

bullrider19 Aug. 13 at 5:21 PM

$MDCX start buying up the warrants under .65 now

0 · Reply

JarvisFlow Aug. 13 at 4:10 PM

D. Boral Capital has adjusted their stance on Medicus Pharma ( $MDCX ), setting the rating to Buy with a target price of 27.

0 · Reply

_www_larval_com_ Aug. 12 at 7:52 PM

$LZMH -6%[7%] $ATNF 4%[214%] $RMSG -4%[28%] $MCVT 3%[17%] $MDCX -3%[11%] most notable movement into the final minutes of trading.

0 · Reply

Stockttwits619 Aug. 12 at 7:33 PM

$CREG $THAR $MDCX $RMSG $LZMH All micros

0 · Reply

2TrustHim Aug. 12 at 2:08 PM

$MDCX What a gift to get in so low!!!

0 · Reply

bullrider19 Aug. 12 at 1:42 PM

$MDCX D.O.A. OUT @$2.03 YESTERDAY wait and see, not looking good, need some news(good)

0 · Reply

2TrustHim Aug. 11 at 6:34 PM

$MDCX Google This This biotech start-up is working overtime to develop a second-wave, mutation-resistant Covid-19 vaccine It could be a little different especially if it works in Cancers!!!

0 · Reply

2TrustHim Aug. 11 at 6:24 PM

$MDCX https://www.hhs.gov/press-room/hhs-winds-down-mrna-development-under-barda.html

0 · Reply

Market Cap	39.55M
Revenue (ttm)	0.00
Net Income (ttm)	-11.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	594,000
Avg Vol	433,856
Day's Range	N/A - N/A
Shares Out	17.82M
Stochastic %K	61%
Beta	N/A
Analysts	Strong Sell
Price Target	$16.15